Harbor Investment Advisory LLC Acquires 2,339 Shares of Edwards Lifesciences Co. (NYSE:EW)

Harbor Investment Advisory LLC lifted its holdings in Edwards Lifesciences Co. (NYSE:EW) by 16.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,383 shares of the medical research company’s stock after purchasing an additional 2,339 shares during the quarter. Harbor Investment Advisory LLC’s holdings in Edwards Lifesciences were worth $1,081,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. Park Avenue Securities LLC lifted its position in shares of Edwards Lifesciences by 0.5% in the second quarter. Park Avenue Securities LLC now owns 23,484 shares of the medical research company’s stock worth $2,169,000 after purchasing an additional 108 shares in the last quarter. City State Bank raised its position in Edwards Lifesciences by 16.5% during the second quarter. City State Bank now owns 917 shares of the medical research company’s stock worth $85,000 after acquiring an additional 130 shares in the last quarter. Chapin Davis Inc. raised its position in Edwards Lifesciences by 1.7% during the first quarter. Chapin Davis Inc. now owns 8,548 shares of the medical research company’s stock worth $817,000 after acquiring an additional 140 shares in the last quarter. Valley National Advisers Inc. raised its position in Edwards Lifesciences by 6.0% during the first quarter. Valley National Advisers Inc. now owns 2,677 shares of the medical research company’s stock worth $255,000 after acquiring an additional 152 shares in the last quarter. Finally, Choreo LLC raised its position in Edwards Lifesciences by 4.1% during the first quarter. Choreo LLC now owns 3,840 shares of the medical research company’s stock worth $367,000 after acquiring an additional 153 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on EW. Citigroup dropped their price target on shares of Edwards Lifesciences from $83.00 to $77.00 and set a “buy” rating on the stock in a research report on Tuesday, October 1st. Wolfe Research raised shares of Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a research report on Monday, July 29th. Piper Sandler dropped their price target on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating on the stock in a research report on Thursday, July 25th. Barclays dropped their price target on shares of Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating on the stock in a research report on Monday, September 9th. Finally, Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating on the stock in a research report on Tuesday, October 1st. Sixteen research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $78.23.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total transaction of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares in the company, valued at $2,051,843.35. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, VP Daveen Chopra sold 1,250 shares of the firm’s stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 11th. The shares were sold at an average price of $66.77, for a total transaction of $333,850.00. Following the completion of the sale, the vice president now owns 46,936 shares in the company, valued at approximately $3,133,916.72. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,250 shares of company stock worth $1,218,138 over the last ninety days. Corporate insiders own 1.29% of the company’s stock.

Edwards Lifesciences Trading Up 0.2 %

EW stock opened at $65.49 on Friday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.87 and a current ratio of 3.71. The company’s 50-day simple moving average is $66.64 and its 200 day simple moving average is $80.99. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a market capitalization of $39.46 billion, a PE ratio of 28.23, a price-to-earnings-growth ratio of 2.80 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. The firm had revenue of $1.63 billion for the quarter, compared to the consensus estimate of $1.65 billion. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.66 earnings per share. As a group, sell-side analysts anticipate that Edwards Lifesciences Co. will post 2.71 earnings per share for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.